Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Research and development - MRTP

Sales, general and administrative

Impairment of intangible assets

Depreciation

Amortization

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

22nd Century Group

22nd Century Group, Inc. is a biotechnology company, which develops disruptive plant-based solutions the for life science, consumer product, and pharmaceutical markets. It focuses on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp or cannabis plants through genetic engineering, gene-editing, and modern plant breeding techniques. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

22nd Century Group advances VLN and GVB units towards profitability

22nd Century Group's Q4 2022 earnings call highlighted progress in VLN tobacco and GVB hemp/cannabis units, with plans for multi-state launches and cash positive operations in 2024. Despite challenges like the Grass Valley facility fire, the company remains focused on achieving profitability through revenue growth and market expansion. Key strengths include successful pilot results, volume growth, and a clear path to cash positivity for both business units.

22nd Century Group (XXII) reports strong Q1 performance and growth strategies

22nd Century Group (XXII) showcases strong performance and strategic initiatives to drive revenue growth and achieve cash positivity by 2024.
Despite challenges such as analyst inquiries and insurance impacts, the company's focus on cost efficiencies and margin improvements positions it for success.
Opportunities in revenue growth, bulk ingredient capacity expansion, and margin enhancements present promising prospects for future profitability and market growth.

22nd Century Group reports strong Q2 performance amidst operational challenges

22nd Century Group's Q2 performance showcased growth in sales but faced challenges in gross profit due to production mix shifts.
The company's proactive strategies for cost savings, brand value creation, and gross margin improvement indicate a focus on long-term sustainability.
Despite challenges like VLN rollout delays and tobacco business hurdles, opportunities in market differentiation and efficiency improvements are being pursued.

22nd Century Group pursues profitability through strategic shifts and cost management

22nd Century Group's Q4 2023 earnings call highlighted efforts to achieve profitability by reducing cash burn, focusing on VLN cigarettes for harm reduction, and exploring CMO opportunities in tobacco manufacturing. Despite challenges like decreased net sales and a negative gross profit, the company aims to reach breakeven by Q1 2025.

22nd Century Group reduces cash burn, aims for profitability by 2025

22nd Century Group's Q1 2024 performance reflects progress towards profitability, with improved financial discipline and operational efficiency.
While facing revenue challenges and legal disputes, the company's strategic initiatives and investor support position it for future growth and success.
The focus on reducing losses, strengthening the balance sheet, and expanding market presence underscores the company's commitment to long-term sustainability.

22nd Century Group reports Q2 financial turnaround and growth strategies

22nd Century Group's Q2 2024 performance reflects a notable financial turnaround and progress towards profitability.
Strategic initiatives, leadership appointments, and product strategies position the company for future growth and success.
While challenges remain in achieving cash positive operations, opportunities in market expansion and product innovation offer avenues for continued advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

22nd Century Group, Inc. is a biotechnology company, which engages in the business of tobacco harm reduction, reduced nicotine tobacco, and improvement of health and wellness through plant science. It operates through the Tobacco and Hemp/Cannabis segments. The Tobacco segment manufactures branded filtered cigars and cigarettes. The Hemp/Cannabis segment focuses on the bulk ingredient distillate or isolate. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

22nd Century Group (XXII) CEO Jim Mish on Q4 2021 Results - Earnings Call Transcript

BUFFALO, N.Y., March 01, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, today reported results for the fourth quarter and full year ended December 31, 2021, and provided an update on recent business highlights. The Company will host a live audio webcast today at 10:00 a.m. ET.

22nd Century Group Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2021

Arena Pharmaceuticals

Clever Leaves Holdings Inc

Flora Growth Corp

HEXO Corp

High Tide

FSD Pharma

Innovative Industrial Properties

Tilray Brands

cbdMD Inc

WM Technology

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we make our way through 2022.

11 Marijuana Stocks on Fire to Close February

First revenue from shipment to in-market partner expected by end of March 2022 First revenue from shipment to in-market partner expected by end of March 2022

22nd Century Group Announces South Korea as First VLN® International Market

FDA's Rulemaking Process Could Make VLN® Menthol King Reduced Nicotine Cigarettes the Only Menthol Cigarette on the Market

22nd Century Group Welcomes Dr. Califf as FDA Commissioner, Urges Action on Menthol and Nicotine in Combustible Cigarettes

New Capabilities Allow 22nd Century to Accelerate Revenue Streams and Create Higher Value Commercial Lines New Capabilities Allow 22nd Century to Accelerate Revenue Streams and Create Higher Value Commercial Lines

22nd Century and KeyGene Achieve Breakthrough in Hemp/Cannabis Plant Transformation

Altria

Philip Morris

The Zacks Tobacco industry players are battling stern government norms and pandemic-led woes like soft duty-free sales. That said, focus on low-risk products bode well for Philip Morris (PM), Altria (MO) and 22nd Century Group (XXII).

3 Tobacco Stocks to Watch Despite Industry Headwinds

Vinco Ventures

Bit Digital, Inc

Exela Technologies

4 penny stocks with high short interest. The post 4 Short Squeeze Penny Stocks To Buy For Under $5 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Short Squeeze Penny Stocks To Buy For Under $5 Right Now

Organic Certification Enables Premium Pricing and Margins Organic Certification Enables Premium Pricing and Margins

22nd Century Secures USDA Organic Certification for Needle Rock Farms

Canopy Growth

Evogene

Neptune Wellness Solutions Inc.

PepsiCo

Dr. Reddy's Labs

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is shaping up as we kick off 2022.

These Pot Stocks Went Wild This Week

22nd Century Group, Inc. XXII announced that it will host a live webcast on Tuesday, March 1, 2022, at 10:00 AM ET to discuss its 2021 fourth quarter and full year results. The company will report its fourth quarter and full year 2021 results in a press release at 6:00 AM ET the same day.

22nd Century Group To Host Q4 & FY 2021 Earnings Call

BUFFALO, N.Y., Feb. 03, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, will host a live webcast on Tuesday, March 1, 2022, at 10:00 AM ET to discuss its 2021 fourth quarter and full year results. 22nd Century will report the Company's fourth quarter and full year 2021 results in a press release at 6:00 AM ET the same day.

22nd Century Group to Announce Fourth Quarter and Full Year 2021 Results on March 1, 2022

VLN® Menthol King Reduced Nicotine Cigarettes Could Be Exempted from Menthol Ban to Help Current Menthol Smokers Transition Away from Highly Addictive Nicotine Cigarettes VLN® Menthol King Reduced Nicotine Cigarettes Could Be Exempted from Menthol Ban to Help Current Menthol Smokers Transition Away from Highly Addictive Nicotine Cigarettes

22nd Century Group Supports Upcoming FDA Action Banning Menthol in Highly Addictive Combustible Cigarettes

BUFFALO, N.Y., Jan. 26, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, today announced production of the first cartons of VLN® King and VLN® Menthol King Cigarettes destined for retail sale as part of the Company's pilot program.

22nd Century Group Announces First Production of VLN® Cigarettes for Retail Sale

GOLDEN, CO / ACCESSWIRE / January 24, 2022 / Panacea Life Sciences, Inc. (OTCQB:PLSH), (the "Company"), a cGMP certified, vertically integrated, premium cannabinoid company, today announced their exclusive agreement with Bright Ideas Unlimited, LLC (BIU), an Amazon.com, Inc. platform partner, to enter the hemp extract world of products within the Amazon marketplace. BIU, which specializes in Amazon go-to-market strategies, content creation and operational excellence, will act as Panacea's exclusive hemp extract partner to launch products on the Amazon platform.

Panacea Life Sciences, Inc. Announces Exclusive Partnership with Amazon Platform Partner Bright Ideas Unlimited, LLC

Further enhances the Board's scientific and commercialization experience supporting key market launches Further enhances the Board's scientific and commercialization experience supporting key market launches

22nd Century Group Appoints James A. Mish to Its Board of Directors

BUFFALO, N.Y., Jan. 18, 2022 (GLOBE NEWSWIRE) -- On December 23, 2021 the FDA announced an historic landmark decision in the fight against smoking when it authorized VLN® King and VLN® Menthol King from 22nd Century Group, Inc. (Nasdaq: XXII) as the first and only reduced nicotine content (RNC) cigarettes under its Modified Risk Tobacco Product (MRTP) designation. Scientific studies show the Company's VLN® reduced nicotine content cigarettes “help you smoke less.” 22nd Century is now moving aggressively to bring VLN® to market. A pilot launch will begin in its first major metropolitan market by March 2022 and then marketing and distribution is expected to expand to a full nationwide launch.

22nd Century Launching the First Reduced Nicotine Cigarette Authorized by the FDA That Helps You Smoke Less

The low-nicotine cigarette maker received the spark it was looking for to jump-start growth.

Why 22nd Century Group Was on Fire in December With a 23% Gain

BUFFALO, N.Y., Jan. 03, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced today that Company management will participate in two fireside chat events on Wednesday, January 5.

22nd Century Group to Participate in Fireside Chat Events with Alliance Global Partners Equity Analyst Aaron Grey and Cowen Equity Analyst Vivien Azer on Wednesday, January 5, 2022

The stock price of 22nd Century Group Inc (NASDAQ: XXII) increased by 38.6% in the previous trading session. This is why it happened.

22nd Century Group Stock (XXII): Why The Price Surged

Why 22nd Century Group Stock Skyrocketed Today

22nd Century Group Rallies 55% Over FDA Approval To Market Its VLN Cigarettes In The U.S.

Agricultural biotech company 22nd Century Group is celebrating an FDA designation. As a result, XXII stock is up 40% today.

XXII Stock Alert: Why Is 22nd Century Group Soaring Higher Today?

BUFFALO, N.Y., Dec. 23, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced today that the U.S. Food and Drug Administration (FDA) has authorized the marketing of the Company's VLN® King and VLN® Menthol King reduced nicotine content cigarettes as modified risk tobacco products (MRTPs). In doing so, the Agency found that VLN® – which smokes, tastes, and smells like a conventional cigarette but contains 95% less nicotine than conventional, highly addictive cigarettes – “help reduce exposure to, and consumption of, nicotine for smokers who use them.”

FDA Authorizes Marketing of 22nd Century Group's VLN® as a Modified Risk Tobacco Product

22nd Century and Aurora Cannabis made an agreement with Cronos Group to license their cannabinoid biosynthesis intellectual property.

News for 22nd Century Group Stock (XXII)